Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmaceuticals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.
Dr. Chang H. Ahn is an internationally recognized drug development expert with over 20 years of experience in the fields of pharmacology and biotechnology. He founded Rexahn in 2001, and currently serves as the company’s Chairman Emeritus and Chief Scientist. From 2001 to February 2013, Dr. Ahn also served as the company’s CEO. Prior, Dr. Ahn held dual positions as both Expert Regulatory Officer and Laboratory Chief at the FDA’s Center for Drug Evaluation and Research. While at the FDA, Dr. Ahn represented the agency in the fields of Antisense Oligonucleotide Therapeutics and Multi-Drug Resistance, and served a key role as both author and co-author of several FDA guidance documents. Before joining the FDA, Dr. Ahn carried out cancer research at the National Cancer Institute and Emory University’s School of Medicine. Dr. Ahn organized and chaired the U.S.-Korea Bio Business and Partnership Forum, of which Maryland State and Montgomery County are partners. He has also served as president of the Society of Biomedical Research since 2000.
Ely Benaim, M.D. has more than 25 years of experience in healthcare including 15 years of clinical research experience in academia, government and pharmaceutical industry as well as extensive experience in global regulatory affairs. Dr. Benaim was most recently Senior Vice President of Regulatory Affairs & Chief Medical Officer of Berg Pharma. Prior to joining Berg Pharma, Dr. Benaim was Global Clinical Development Leader at Millennium/Takeda Pharmaceuticals where he oversaw global clinical development of the Aurora A kinase inhibitor program. Prior to joining Takeda in 2011, Dr. Benaim served as Vice President of Clinical Affairs for Sangamo BioSciences where he lead the development of zinc-fingers transcription factors cellular therapies in the areas of Cancer, Diabetes, Neurology, Cardiovascular and HIV. Before Sangamo, Dr. Benaim served at Amgen as Global Clinical Lead for the development of rilotumumab, a hepatocyte growth factor antibody for solid tumors, currently in late stage development. Prior to Amgen he was a Senior Director, Oncology Clinical Development at Salmedix/Cephalon Inc. (now Teva, Inc.) where he led the development of TREANDA® to a Phase 3 pivotal trial for lymphoma. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude's Children's Research Hospital, in Memphis, Tennessee. From 1997 to 2004, he was Assistant Professor in the Department of Pediatrics at the University of Tennessee and an Assistant Member to the Department of Hematology/Oncology. As a member of the Transplantation and Gene Therapy program he published several manuscripts on the areas of stem cell transplantation, immunology and gene therapy. Dr. Benaim also has a passion for global pediatric cancer awareness and care and has been awarded for his contributions in Latin America and the United States.
Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 20 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University.
Lisa Nolan, Ph.D. joined Rexahn as Chief Business Officer in July 2016. Dr. Nolan previously served as Chief Business Officer at Relmada Therapeutics. Prior to this, she was Managing Director of Nolex Advisors, LLC, where she led successful competitive processes for out-licensing of early and late-stage pharmaceutical products. Over the course of her career, Ms. Nolan has held various leadership roles at biopharmaceutical companies including Chief Business Officer at Topigen Pharmaceuticals, where she championed and led the acquisition of Topigen by Pharmaxis. Additionally, she served as Vice President, Global Business Development and Strategic Marketing for SkyePharma Inc., where she completed over a dozen out-licensing deals in the U.S. and Europe with deal values ranging in excess of $500 million. Ms. Nolan holds a Ph.D. in clinical pharmacology and a M.Sc., and B.Sc., in pharmacy from Trinity College in Dublin, Ireland.